Pursuant to regulation 30 of SEBI (listing Obligation and disclosure requirements), 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem India reported its unaudited financial results for the quarter and nine months ended December 31, 2025, with a clean (unmodified) limited review report from statutory auditors Stav & Co. Revenue from operations for Q3 FY26 stood at Rs 16,164 lakhs, up sharply from Rs 9,112 lakhs in the same quarter last year, while nine-month revenue jumped to Rs 40,632 lakhs versus Rs 24,748 lakhs in the prior period, a rise of around 64%. Profit after tax for the nine months turned strongly positive at Rs 774 lakhs compared to a near-breakeven Rs 0.02 lakhs a year earlier, and Q3 PAT rose to Rs 417 lakhs from Rs 50 lakhs. The Board also approved a ~Rs 14 crore expansion of its existing plant at Village Bargodam, Panchkula, adding new manufacturing capacity for Amoxicillin and Ampicillin, expanding the CDF unit, and upgrading the Effluent Treatment Plant, with commissioning targeted by December 2026, funded through internal accruals and borrowings. Additionally, a revised Related Party Transactions Policy was adopted to align with the latest SEBI circular.
Strong revenue and profit growth, combined with capacity expansion plans and a clean audit, signal improving business momentum and potential for sustained earnings growth, which is positive for shareholders. The Rs 14 crore capex funded partly by borrowings may add modest leverage, but the expected commissioning by Dec 2026 supports the growth outlook.